Last reviewed 2026-04-20 · How we verify
Home › Drugs › University Hospital, Basel, Switzerland › Donor-derived ex-vivo expanded EBV Tscm CTL Donor-derived ex-vivo expanded EBV Tscm CTL
At a glance
Generic name Donor-derived ex-vivo expanded EBV Tscm CTL Sponsor University Hospital, Basel, Switzerland Modality Small molecule Phase Phase 1
Approved indications
No approved indications tracked.
Common side effects
No common side effects on file.
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
Drug Landscape https://druglandscape.com/drug/donor-derived-ex-vivo-expanded-ebv-tscm-ctl · Machine-readable: markdown · JSON · Editorial policy: /editorial-policy
Not medical advice. Information on this page is collated from primary regulatory and clinical-trial sources for research purposes. It is not a substitute for consultation with a licensed healthcare professional. See our editorial policy for sourcing and methodology.